RE: Halfway thru' April, full year results coming...15 Apr 2025 10:34
Think we know the FY 24 results, more or less, given Europe will be held as discontinued.
Sales £4M
Operating Costs, this is the hard one. How much of the £40M goes with Europe and how much remains. My guess £20M is cost base of new CREO so -£16M loss at PBT level. Maybe higher due to costs of selling Europe. The real question is what is management expectation for 2025 sales of core and Kamaptive. £6M, £8M, or £10M. Kamaptive did zero in 2024 but £1.7m in 2023. As this trades on a multiple of sales at the moment and hopefully the FY operating costs are circa £20m, the forward guidance on sales is the only thing that matters and maybe why they held 49% of Europe and what the plans are for this stake. Valuing this thing is hard as it all starts with the sales number. When you are guessing whether that is 50%, 100% or 200% growth it is a bit of crystal ball gazing.